Revelation Biosciences Inc. (NASDAQ: REVB)

Introduction

Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2020, the company develops Gemini, an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD®) designed to reprogram the innate immune system and mitigate inflammatory damage associated with trauma, infection, and other stresses.

Corporate Structure

• Headquarters: San Diego, CA
• Founded: 2020
• Industry: Biotechnology Research
• Company Type: Public
• Employees: 11–50 (as reported on LinkedIn)

Recent Developments and News

• April 29, 2025: Revelation announced a new indication (GEM-PBI) for Gemini, aimed at preventing infection in severe burn patients requiring hospitalization, in collaboration with Vanderbilt University.
• Q1 2025: The company reported Phase 1 clinical data indicating that intravenous administration of Gemini met its primary safety endpoint and showed statistically significant upregulation of IL-10.
• May 28, 2025: The SEC declared the Form S-1 registration statement effective, allowing the company to proceed with its planned public offering.
• May 29, 2025:
  • Filed a Prospectus (Rule 424(b)(3)) for a public offering of 675,000 common shares at $1.10 each, pre-funded warrants for up to 2,965,000 shares, and Class H warrants for 14,560,000 shares.
  • Submitted a preliminary proxy statement (PRE 14A) prior to the annual meeting, addressing governance matters.

Financial and Strategic Aspects

Trading and Capital Structure (as of June 3, 2025)

Metric	Value
Share Price	$1.04
Daily Change	+26.37%
Volume	6,961,763
52-Week Range	$0.775 – $60.80
Market Cap (intraday)	$1.01 M
Average Daily Volume	169,785
Last Close (May 28, 2025)	$0.823

Key Financial Metrics (TTM/MRQ)

• Net Income (ttm): –$14.41 M
• Diluted EPS (ttm): –$82.07
• Total Cash (mrq): $3.7 M
• Profit Margin: 0.00%
• Return on Assets (ttm): –54.68%
• Return on Equity (ttm): –233.26%

Strategic Initiatives

• Capital Raise: The May 29, 2025, prospectus outlines plans to fund research and development, clinical development, and regulatory activities.
• Reverse Stock Splits: A 1-for-30 reverse split was executed on January 25, 2024, followed by a 1-for-16 reverse split on January 28, 2025, to align the share price with market requirements.
• Pipeline Expansion:
  • GEM-AKI: A program focused on the prevention of acute kidney injury.
  • GEM-CKD: Developing treatments aimed at slowing the progression of chronic kidney disease.
  • GEM-PSI: Targeting prevention or reduction of post-surgical and healthcare-associated infections.
  • GEM-PBI: A program initiated on April 29, 2025, aimed at preventing infection in severe burn patients.

Market Position and Industry Context

• Sector: Clinical-stage immunotherapies focused on trained immunity.
• Comparable Companies: Micro- and small-cap biopharmaceutical firms with early-stage pipelines.
• Competitive Factors:
  • Addressing unmet medical needs in acute and chronic inflammatory conditions.
  • Navigating regulatory pathways for novel immunomodulators.
  • Securing access to capital and establishing strategic partnerships, such as the collaboration with Vanderbilt University.

TL;DR

• On June 3, 2025, REVB shares increased by 26.37% to $1.04 on NASDAQ, with a trading volume of 6.96 million shares.
• April 29, 2025: The company announced the GEM-PBI program, aimed at preventing infections in severe burn patients.
• Q1 2025: Phase 1 clinical data for Gemini met safety endpoints and exhibited biomarker activity (IL-10 upregulation).
• May 28-29, 2025: The SEC deemed the Form S-1 effective and a prospectus was filed for a public offering of 675,000 shares and associated warrants.
• Upcoming catalysts include clinical data readouts for GEM-AKI and GEM-PSI, along with potential regulatory filings; earnings are scheduled for August 7-11, 2025.